 |
市场调查报告书
商品编码
1970454
全球生长激素市场规模、份额、趋势和成长分析报告（2026-2034年）Global Growth Hormone Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
预计2026年至2034年间，生长激素市场将以6.42%的复合年增长率成长，从2025年的45.3亿美元成长到2034年的79.4亿美元。
受生长激素缺乏症盛行率上升、儿童和成人内分泌疾病认知度提高以及治疗应用范围不断扩大的推动，全球生长激素市场预计将呈现强劲增长。生长激素荷尔蒙疗法对于治疗透纳氏症、慢性肾衰竭和原发性矮小症疾病至关重要。除了传统应用外，研究还揭示了其在代谢健康、肌肉萎缩症和再生医学等领域的更广泛用途，进一步推动了市场未来的成长。
药物递送系统的技术进步是主要驱动力。长效製剂、缓释注射剂和无针给药装置等创新技术正在提高患者的用药依从性和治疗效果。生物相似药也透过提高药物的可近性和可负担性，尤其是在医疗保健投资不断增长的新兴经济体中，正在改变市场动态。同时，主要企业正在推动生物技术方法，以确保重组生长激素生产更有效率且经济。
生物技术与精准医疗的融合将塑造生长激素市场的未来。基因谱分析和个人化治疗将优化治疗方案，从而减少副作用并提高疗效。生长激素荷尔蒙疗法在老龄化相关疾病和健康促进领域的应用日益广泛，进一步扩大了市场范围。随着临床开发平臺的不断扩充和监管核准的加速推进，市场可望提供创新且以患者为中心的解决方案，重新定义内分泌治疗和人类健康促进的标准。
目录
第一章：引言
第二章执行摘要
第三章 市场变数、趋势与框架
- 市场谱系展望
- 渗透率和成长前景分析
- 价值链分析
- 法律规范
- 标准与合规性
- 监管影响分析
- 市场动态
- 市场驱动因素
- 市场限制因素
- 市场机会
- 市场挑战
- 波特五力分析
- PESTLE分析
第四章：全球生长激素市场：依产品划分
- 市场分析、洞察与预测
- 粉末
- 溶剂
第五章：全球生长激素市场：依应用领域划分
- 市场分析、洞察与预测
- 生长激素缺乏症
- 原发性矮小症
- 透纳氏症
- 相对于胎龄而言，出生体重偏低的婴儿
- 普拉德-威利症候群
- 其他用途
第六章：全球生长激素市场：依通路划分
- 市场分析、洞察与预测
- 医院药房
- 零售药房
- 网路药房
第七章：全球生长激素市场：依地区划分
- 区域分析
- 北美市场分析、洞察与预测
- 我们
- 加拿大
- 墨西哥
- 欧洲市场分析、洞察与预测
- 英国
- 法国
- 德国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太市场分析、洞察与预测
- 印度
- 日本
- 韩国
- 澳洲
- 东南亚
- 其他亚太国家
- 拉丁美洲市场分析、洞察与预测
- 巴西
- 阿根廷
- 秘鲁
- 智利
- 其他拉丁美洲国家
- 中东和非洲市场分析、洞察与预测
- 沙乌地阿拉伯
- UAE
- 以色列
- 南非
- 其他中东和非洲国家
第八章 竞争情势
- 最新趋势
- 公司分类
- 供应链和销售管道合作伙伴（根据现有资讯）
- 市场占有率和市场定位分析（基于现有资讯）
- 供应商情况（基于现有资讯）
- 策略规划
第九章：公司简介
- 主要公司的市占率分析
- 公司简介
- Novo Nordisk A/S
- Novartis AG
- Merck KGaA
- Anhui Anke Biotechnology（Group）Co. Ltd
- Pfizer Inc
- Eli Lilly And Company
- Ipsen SA
- Zhongshan Sinobioway Hygene Biomedicine Co. Ltd
- Sandoz International GmbH
- AnkeBio Co. Ltd
The Growth Hormone Market size is expected to reach USD 7.94 Billion in 2034 from USD 4.53 Billion (2025) growing at a CAGR of 6.42% during 2026-2034.
The global growth hormone market is poised for strong expansion, fueled by rising prevalence of growth hormone deficiencies, increasing awareness of pediatric and adult endocrine disorders, and expanding therapeutic applications. Growth hormone therapies are vital for addressing conditions such as Turner syndrome, chronic renal insufficiency, and idiopathic short stature. Beyond traditional uses, research is uncovering broader applications in metabolic health, muscle wasting disorders, and regenerative medicine, adding significant depth to the market's future growth trajectory.
Technological progress in drug delivery systems is a key driver. Innovations such as long-acting formulations, sustained-release injectables, and needle-free delivery devices are improving patient adherence and treatment outcomes. Biosimilars are also reshaping market dynamics by increasing accessibility and affordability, particularly in emerging economies with rising healthcare investments. Meanwhile, leading pharmaceutical companies are advancing biotechnological methods to ensure more efficient and cost-effective production of recombinant growth hormones.
The future of the growth hormone market will be shaped by the convergence of biotechnology and precision medicine. Genetic profiling and personalized therapies are expected to optimize treatment regimens, reducing adverse effects and enhancing efficacy. The growing use of growth hormone therapies in age-related conditions and wellness applications further broadens the market scope. As clinical pipelines expand and regulatory approvals accelerate, the market is positioned to deliver innovative, patient-friendly solutions that redefine standards in endocrine therapy and human health enhancement.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Product
- Powder
- Solvent
By Application
- Growth Hormone Deficiency
- Idiopathic Short Stature
- Turner Syndrome
- Small for Gestational Age
- Prader-Willi Syndrome
- Other Applications
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Medstores
COMPANIES PROFILED
- Novo Nordisk AS, Novartis AG, Merck KGaA, Anhui Anke Biotechnology Group Co Ltd, Pfizer Inc, Eli Lilly and Company, Ipsen SA, Zhongshan Sinobioway Hygene Biomedicine Co Ltd, Sandoz International GmbH, AnkeBio Co Ltd
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL GROWTH HORMONE MARKET: BY PRODUCT 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Product
- 4.2. Powder Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Solvent Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL GROWTH HORMONE MARKET: BY APPLICATION 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Application
- 5.2. Growth Hormone Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Idiopathic Short Stature Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Turner Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.5. Small for Gestational Age Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.6. Prader-Willi Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.7. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL GROWTH HORMONE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Distribution Channel
- 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Online Medstores Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL GROWTH HORMONE MARKET: BY REGION 2022-2034(USD MN)
- 7.1. Regional Outlook
- 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Product
- 7.2.2 By Application
- 7.2.3 By Distribution Channel
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
- 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Product
- 7.3.2 By Application
- 7.3.3 By Distribution Channel
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
- 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Product
- 7.4.2 By Application
- 7.4.3 By Distribution Channel
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
- 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Product
- 7.5.2 By Application
- 7.5.3 By Distribution Channel
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
- 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Product
- 7.6.2 By Application
- 7.6.3 By Distribution Channel
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa
Chapter 8. COMPETITIVE LANDSCAPE
- 8.1. Recent Developments
- 8.2. Company Categorization
- 8.3. Supply Chain & Channel Partners (based on availability)
- 8.4. Market Share & Positioning Analysis (based on availability)
- 8.5. Vendor Landscape (based on availability)
- 8.6. Strategy Mapping
Chapter 9. COMPANY PROFILES OF GLOBAL GROWTH HORMONE INDUSTRY
- 9.1. Top Companies Market Share Analysis
- 9.2. Company Profiles
- 9.2.1 Novo Nordisk A/S
- 9.2.2 Novartis AG
- 9.2.3 Merck KGaA
- 9.2.4 Anhui Anke Biotechnology (Group) Co. Ltd
- 9.2.5 Pfizer Inc
- 9.2.6 Eli Lilly And Company
- 9.2.7 Ipsen S.A
- 9.2.8 Zhongshan Sinobioway Hygene Biomedicine Co. Ltd
- 9.2.9 Sandoz International GmbH
- 9.2.10 AnkeBio Co. Ltd
